NeuroClearance · Hardware for the brain’s own maintenance biology
Your brain cleans, powers and repairs itself every night. We are building the hardware to work with it.
The decline of those systems is linked to Alzheimer’s, Parkinson’s and the cognitive losses of aging. Medicine has drugs for the brain’s chemistry and almost no hardware for its physics: the movement of fluid, the delivery of energy, the timing of sleep. NeuroClearance is building that hardware, precisely controlled and independently verified, from an affordable research instrument to FDA-authorized devices to a coordinated platform for recovery. Six U.S. patent filings describe the architecture. The founder has built and sold three hard-technology companies. The plan is designed to be checked.
The problem
The brain’s maintenance systems fail quietly, and the cost is enormous.
In 2012 researchers described a brain-wide pathway that moves cerebrospinal fluid through brain tissue and carries waste out. In 2019, imaging of sleeping people showed the neural, blood-volume and fluid rhythms that drive it. The same decade showed how clearance, energy supply, blood flow and immune maintenance weaken with age and in neurodegenerative disease.
Almost all of that knowledge was won with equipment that only a handful of laboratories own. There is no affordable, reproducible hardware for working with these systems, which is why so little of what has been learned has reached people.
These figures describe the scale of the need. They are not a statement of NeuroClearance’s market, and nothing we build is a treatment.
The idea
Treat the brain’s physics with the seriousness medicine gives its chemistry.
Fluid flow, energy delivery, vascular tone and the timing of sleep are physical quantities. Physical quantities can be measured directly, controlled precisely, and checked by independent instruments. That makes the question of whether the brain’s own maintenance systems can be supported a question engineering can answer.
NeuroClearance’s architecture does three things no drug can: it measures what it delivers, it responds to how the body answers, and it hands a separate safety system the authority to stop everything. Those principles are the core of our filings, and they scale from a bench instrument to the coordinated, multi-modality systems where this work is headed.
Where this goes
One platform. Three ways it reaches people.
The same control-and-measurement architecture is being carried along three product tracks, each with its own evidence standard and regulatory route.
An affordable research and clinical instrument
Bench instrument first, then independent verification, supervised studies with clinical collaborators and a formal regulatory determination. The goal is a unit authorized by FDA for its intended use and priced so that laboratories and clinics can own one.
A consumer line for everyday self-improvement
Lullwave is a separate consumer line intended to fit FDA’s general-wellness policy for low-risk products: wellness claims only, no diagnosis or treatment, and no dependence on the regulated track’s timeline. Counsel review of that fit is part of the plan. Nothing is for sale yet.
Coordinated systems for rehabilitation and recovery
The direction described in our filings: coordinated, multi-modality systems that support recovery and rehabilitation under supervision, with each modality added only after its own measurement, independent review and safety case. A research hypothesis with no timeline and no claim of benefit.
Why NeuroClearance
A hard-technology team, a protected platform, and a plan built to be checked.
Hard technology, shipped
The founder took PolyStrata® microfabrication from a DARPA program to ISO 9001 and AS9100D certified production and a $64 million acquisition by Cubic Corporation, after building and selling two earlier optoelectronics companies. Named inventor on more than 125 U.S. patent filings.
Six U.S. patent filings
Six U.S. provisional applications have been filed, with more in preparation as the research and technical portfolio grows. They describe a platform rather than a single device: measured delivery, response-controlled operation, independent safety supervision, reconstructable records, and the staged extensions that follow, including sleep-state coordination and coordinated multi-modality systems.
Evidence before claims
Every controlled quantity is measured by an instrument independent of the one controlling it. Results, including failures, are published as approved summaries and reviewed by people outside the program. Claims of benefit follow the evidence and the regulators, in that order.
Where we are
First bench unit under assembly.
Components for the first bench configuration are in hand and the unit is being integrated. The next milestone is a measurement-characterization report, reviewed by someone outside the program. Research stage; nothing on this site is a treatment or a product. One dated status record is kept in step with mneos.ai.
The people building it
Founder-led, with named roles.
David Sherrer
Founder and program lead
Accountable for technical direction, program decisions and every public statement on this site. Founded Nuvotronics, which carried PolyStrata® microfabrication from a DARPA program to certified production and was acquired by Cubic Corporation in 2019; earlier founded Haleos and ACT MicroDevices in optoelectronic packaging. Named inventor on more than 125 issued and pending U.S. patent applications across those companies, all assigned to the acquirers.
- EngineeringNuvoNexus and MacroVation engineering teams: assembly, test fixtures and quality systems.
- CounselOutside regulatory counsel and outside patent counsel.
- AdvisorsListed only with written consent as they join. Two independent reviewer roles are open now. Open research needs
Track record refers to the founder’s prior companies and is not a claim about NeuroClearance results.
Work with NeuroClearance
Two routes, each with a clear next step.
Investors
A public brief covers the thesis, the current stage, the intended research value, the founder’s verified history and the next financed milestone. Deeper materials follow a fit conversation under agreement.
Read the investor briefScientific and clinical collaborators
Three open research needs, each with a defined first contribution:
- A calibration, timing and uncertainty plan for the bench configuration
- An endpoint and alternative-explanations review for later studies
- Regulatory and study-design input for the research-readiness stage
We design for rigorous evidence, patient safety and broad access, with a sustainable commercialization model. Our commitments →
Learn and follow progress
Start with three explainers, then follow the bench.
What is brain clearance?
The pathway described in 2012, what sleep has to do with it, and what remains debated.
Read → FrontiersRecent advances, 2023 to 2026
Disease-modifying Alzheimer’s drugs, the first blood test, and a large negative trial every reader should know about.
Read → Reading guideHow to read brain-health evidence
Five questions to ask of any claim, including ours.
Read →Status synchronized with MNEOS; investor brief and team page published
Components for the first bench configuration arrived in late September and assembly has begun. The next milestone is measurement characterization.